Today, Comera Life Sciences, Inc. (“Comera” or the “Company”)
and Intas Pharmaceuticals Ltd. (“Intas”) announced a research
collaboration to develop a new generation of bio-innovative
biologic medicines to improve patient access, safety, and
convenience.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220418005526/en/
Under the terms of the partnership agreement, Comera will
develop a differentiated formulation of an Intas product using
Comera’s innovative proprietary SQore™ formulation platform. Intas
will initially provide research funding with the option to acquire
global rights to the formulation through an exclusive license with
responsibility for subsequent development and
commercialization.
“We are excited to work with Comera to enhance therapeutic
options and access for patients,” said Binish Chudgar, Vice
Chairman and Managing Director of Intas Pharmaceuticals. “This
collaboration will accelerate our quest to develop innovative,
value-added medicines that can make a difference in patients' lives
globally,” he added.
“This collaboration is the latest step in our long-term
partnership strategy to leverage our SQore platform and transition
from preclinical, early-stage assets to late-stage, marketed
products,” said Jeff Hackman, Chief Executive Officer and Chairman
of Comera. “We look forward to working with Intas and developing a
differentiated formulation that will make it easier for patients to
use and increase healthcare savings.”
About Comera Life Sciences
Leading a compassionate new era in medicine, Comera Life
Sciences is applying a deep knowledge of formulation science and
technology to transform essential biologic medicines. The goal of
this approach is to provide patients with the freedom of
self-injectable care, reduce institutional dependency and to put
patients at the center of their treatment regimen. On January 31,
2022, Comera Life Sciences and OTR Acquisition Corp. (Nasdaq: OTRA)
(“OTR”), a publicly traded special purpose acquisition company
(SPAC), announced a proposed business combination.
To learn more about the Comera Life Sciences mission, as well as
the proprietary SQore™ platform, visit
https://comeralifesciences.com/.
About Intas Pharmaceuticals
Intas Pharmaceuticals Ltd. is a leading vertically integrated
pharmaceutical company based in Ahmedabad, India, having end-to-end
capabilities of formulation development, manufacturing and
marketing along with backward integration of APIs. The organisation
has more than 18,000 employees and 14 manufacturing sites worldwide
and sells products in more than 85 countries. The Intas Group's
revenue amounted to USD 2.2 bn in FY 2020-21 and the compounded
annual growth rate of revenue has been 19% in the past 5 years.
For more information, please visit www.intaspharma.com.
Forward-Looking Statements
This press release contains includes “forward-looking
statements” within the meaning of the federal securities laws.
These forward-looking statements generally are identified by the
words “believe,” “project,” “expect,” “anticipate,” “estimate,”
“intend,” “strategy,” “future,” “opportunity,” “plan,” “may,”
“should,” “will,” “would,” “will be,” “will continue,” “will likely
result,” and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this document, including, but not
limited to: (i) the risk that the transaction may not be completed
in a timely manner or at all, which may adversely affect the price
of OTR’s securities, (ii) the risk that the transaction may not be
completed by OTR’s business combination deadline and the potential
failure to obtain an extension of the business combination deadline
if sought by OTR, (iii) the failure to satisfy the conditions to
the consummation of the transaction, including the adoption of the
business combination agreement by the stockholders of OTR, the
satisfaction of the minimum trust account amount following
redemptions by OTR’s public stockholders, (iv) the lack of a third
party valuation in determining whether or not to pursue the
proposed business combination, (v) the occurrence of any event,
change or other circumstance that could give rise to the
termination of the business combination agreement, (vi) the effect
of the announcement or pendency of the transaction on Comera’s
business relationships, performance, and business generally, (vii)
risks that the proposed business combination disrupts current plans
of Comera and potential difficulties in Comera’s employee retention
as a result of the proposed business combination, (viii) the
outcome of any legal proceedings that may be instituted against
Holdco, Comera or OTR related to the business combination agreement
or the proposed business combination, (ix) the ability to maintain
the listing of OTR’s securities on the Nasdaq, (x) the price of
Holdco’s securities may be volatile due to a variety of factors,
including changes in the competitive and highly regulated
industries in which Comera operates, variations in performance
across competitors, changes in laws and regulations affecting
Comera’s business and changes in the combined capital structure,
(xi) the ability to implement business plans, forecasts, and other
expectations after the completion of the proposed business
combination, and identify and realize additional opportunities,
(xii) the risk of downturns and the possibility of rapid change in
the highly competitive industry in which Comera operates, (xiii)
the risk that Comera and its current and future collaborators are
unable to successfully develop and commercialize Comera’s products
or services, or experience significant delays in doing so, (xiv)
the risk that Comera may never achieve or sustain profitability;
(xv) the risk that Comera will need to raise additional capital to
execute its business plan, which many not be available on
acceptable terms or at all; (xvi) the risk that the
post-combination company experiences difficulties in managing its
growth and expanding operations, (xvii) the risk that third-parties
suppliers and manufacturers are not able to fully and timely meet
their obligations, (xviii) the risk of product liability or
regulatory lawsuits or proceedings relating to Comera’s products
and services, and (xix) the risk that Comera is unable to secure or
protect its intellectual property and (xx) the risk that the
post-combination company’s securities will not be approved for
listing on Nasdaq or if approved, maintain the listing. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of OTR’s
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q,
Holdco’s registration statement on Form S-4 and the proxy
statement/prospectus discussed above and other documents filed by
Holdco or OTR from time to time with the SEC. These filings
identify and address other important risks and uncertainties that
could cause actual events and results to differ materially from
those contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Holdco, Comera and OTR assume no obligation and do not intend
to update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Neither
Holdco, Comera nor OTR gives any assurance that either Comera or
OTR will achieve its expectations.
Important Information About the Proposed Business Combination
and Where to Find It
In connection with the proposed business combination, Comera
Life Sciences Holdings, Inc. (“Holdco”) has filed a Registration
Statement on Form S-4 which include a proxy statement of OTR and a
prospectus of Holdco. The definitive proxy statement/prospectus
will be sent to all OTR and Comera stockholders. Holdco and OTR
will also file other documents regarding the proposed business
combination with the SEC. Before making any voting decision,
investors and securities holders of OTR and Comera are urged to
read the proxy statement/prospectus and all other relevant
documents filed or that will be filed with the SEC in connection
with the proposed business combination as they become available
because they will contain important information about the proposed
business combination and the parties to the proposed business
combination. Investors and securities holders will be able to
obtain free copies of the proxy statement/prospectus and all other
relevant documents filed or that will be filed with the SEC by
Holdco through the website maintained by the SEC at
https://sec.gov/. In addition, the documents filed by OTR may be
obtained free of charge from OTR’s website at
https://otracquisition.com/investors/ or by written request to OTR
Acquisition Corp., 1395 Brickell Avenue, Suite 800, Miami, Florida
33131.
Participants in the Solicitation
Holdco, OTR and Comera and their respective directors and
officers may be deemed to be participants in the solicitation of
proxies from OTR’s stockholders in connection with the proposed
business combination. Information about OTR’s directors and
executive officers and their ownership of OTR’s securities is set
forth in OTR’s filings with the SEC. To the extent that holdings of
OTR’s securities have changed since the amounts printed in OTR’s
Annual Report, such changes have been or will be reflected on
Statements of Change in Ownership on Form 4 filed with the SEC.
Additional information regarding the interests of those persons and
other persons who may be deemed participants in the proposed
business combination may be obtained by reading the preliminary
proxy statement/prospectus included in the Registration Statement
on Form S-4 filed by Holdco with the SEC regarding the proposed
business combination. You may obtain free copies of these documents
as described in the preceding paragraph.
No Offer or Solicitation
This communication shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be
any sale of securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction.
No offering of securities shall be made except by means of a
prospectus meeting the requirements of Section 10 of the Securities
Act.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220418005526/en/
Comera Investor Contact
John Woolford ICR Westwicke John.Woolford@westwicke.com
Comera Press Contact
Sean Leous ICR Westwicke Sean.Leous@westwicke.com
Intas Media Contact
Vibhuti Bhatt vibhutibhatt@oneadvt.com 9824079734
OTR Acquisition (NASDAQ:OTRA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
OTR Acquisition (NASDAQ:OTRA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024